Communiqués NexImmune, Inc.

Actions

NEXI

US65344D2080

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 17/06/2024			Varia. 5j.	Varia. 1 janv.
2,95 ^USD	0,00%		+8,06%	+32,88%

20/05	NexImmune, Inc. déclare ses résultats pour le premier trimestre terminé le 31 mars 2024	CI
16/04	NexImmune, Inc. déclare ses résultats pour l'exercice complet terminé le 31 décembre 2023	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	02/02	AQ
Bull Run 2024: Biopharma Healthcare Stocks Surge, Gaining Momentum: DYAI, ABVC, FWBI, VTAK, NEXI	08/01	AQ
Neximmune : Failure to Satisfy Listing Rule - Form 8-K	01/12	PU
NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes	24/10/23	AQ
NexImmune Announces Presentations at The Society for Immunotherapy of Cancer’s 38th Annual Meeting	19/10/23	GL
NexImmune Announces Presentations at The Society for Immunotherapy of Cancer’s 38th Annual Meeting	19/10/23	AQ
NexImmune Announces 1-for-25 Reverse Stock Split	18/10/23	GL
NexImmune Announces 1-for-25 Reverse Stock Split	18/10/23	AQ
NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy	31/08/23	GL
NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy	31/08/23	AQ
NexImmune Reports Second Quarter 2023 Financial Results and Provides Business Updates	10/08/23	GL
NexImmune : Robust immune response with clinical activity at the highest dose level with one patient achieving no evidence of disease 7 months post-infusion with NEXI-001 - Form 8-K	05/06/23	PU
NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting	05/06/23	AQ
NexImmune Announces Poster Presentation at the 2023 FOCIS Annual Meeting	22/05/23	AQ
NEXIMMUNE, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	15/05/23	AQ
NexImmune Reports First Quarter 2023 Financial Results and Provides Business Updates	15/05/23	GL
NEXIMMUNE, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events (form 8-K)	26/04/23	AQ
NexImmune Announces Presentation of Phase 1/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting	26/04/23	AQ
NEXIMMUNE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	28/03/23	AQ
NEXIMMUNE, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	28/03/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués NexImmune, Inc.

Actions

NEXI

US65344D2080

Communiqués

Filtres